Inhibitor Therapeutics, Inc. (OTCPK: INTI)
Health Care · Biotechnology · US
$0.11
+12.14% today · +141.5% 1Y
Inhibitor Therapeutics, Inc. (OTCPK: INTI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $19.10M and employs 8 people.
Over the last twelve months the share price has gained 141.5%, trading between 0.04 and 0.12.
Tweenvest scores Inhibitor Therapeutics, Inc. across four factors: quality 36/100, value 92/100. Its strongest factor is value.
INTI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $19.10M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- -0.68
- 52-week high
- $0.12
- 52-week low
- $0.04
- Avg volume (3M)
- —
- Shares outstanding
- 173.79M
- Employees
- 8
- Next earnings
- —
About Inhibitor Therapeutics, Inc.
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
- ISIN
- US45720M1053
- Founded
- 1992
- Listed since
- Sep 13, 2013
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Modalis Therapeutics CorporationTSE: 4883 | $19.56M | ¥29.00 | -3.33% |
| Elicera Therapeutics AB (publ)OM: ELIC | $19.51M | Skr2.90 | +5.08% |
| Nexsen LimitedASX: NXN | $19.50M | AU$0.14 | +7.69% |
| Resverlogix Corp.TSX: RVX | $19.47M | CA$0.08 | -5.88% |
| GenSight Biologics S.A.ENXTPA: SIGHT | $19.05M | €0.07 | -5.00% |
| HST Global, Inc.OTCPK: HSTC | $18.91M | $0.13 | -80.90% |
| Dextech Medical ABXSAT: DEX | $18.89M | Skr— | — |
| General Biologicals CorporationTPEX: 4117 | $18.79M | NT$8.61 | -8.31% |
Figures last refreshed Oct 18, 2026.